Savitz AJ, et al. – The efficacy and safety of paliperidone palmitate three–monthly (PP3M) formulation were investigated in an East Asian population with schizophrenia by subgroup analysis of a double–blind (DB), multicenter, noninferiority study. The clinicians suggested that in the East Asian subgroup, PP3M was efficacious. No new safety signals were identified although treatment–emergent adverse events were slightly higher in the East Asian subgroup versus the global population.